ZPR1 Genotype

A small change in a single gene called ZPR1 (zinc finger protein 1, also known as ZNF259) can quietly tilt your odds toward higher triglycerides, harder-to-control blood sugar, fatty liver, and earlier heart attacks. The gene sits inside one of the most influential fat-handling regions of the human genome, right next to the cluster that codes for apolipoproteins A1, C3, A4, and A5.

You can carry the at-risk version of ZPR1 and still see a textbook lipid panel in your twenties or thirties. The problem shows up later, often as triglyceride creep, prediabetes, or a coronary event that comes earlier than your family history alone would predict. Knowing your genotype lets you start adjusting decades before any of that arrives.

What ZPR1 Actually Does

ZPR1 makes a regulatory protein that helps cells respond to growth and metabolic signals. It moves from the cytoplasm into the nucleus when cells receive growth signals, and it is required for normal cell division. The gene sits inside the same chromosomal neighborhood as APOA5, APOC3, APOA4, and APOA1, which together coordinate how your liver packages triglycerides and how your tissues clear fat from the bloodstream after a meal.

This test looks at specific single-letter changes (called SNPs) in or around the ZPR1 gene. The most studied is rs964184, where a single base change from C to G is the marker tracked in most of the published evidence. Other variants in the same region, including rs2075290, rs2075294, and rs6589566, have been linked to similar metabolic and cardiovascular patterns in different populations.

Heart Attack Risk

The clearest signal comes from people who already carry an inherited cholesterol disorder. In a study of 725 adults with familial hypercholesterolemia (a genetic condition that drives lifelong high LDL), rs964184 was significantly tied to heart attack (hazard ratio about 5.7) even after accounting for the usual cardiovascular risk factors like LDL cholesterol, blood pressure, and smoking. The genotype added information that standard risk scoring missed.

Other ZPR1 variants have been linked to coronary artery disease in independent groups. In a cohort of 1,024 adults from southern India, rs6589566 and rs2075294 showed meaningful associations with coronary disease and its severity. Across populations, this region consistently shows up as a coronary risk locus, not a curiosity.

One important caveat: in a prospective study of 5,547 patients who already had clinically manifest vascular disease, rs964184 was strongly tied to triglyceride levels but was not linked to recurrent vascular events (hazard ratio 0.99). The variant looks most useful for predicting a first event, not for forecasting what happens after one.

Triglycerides and Cholesterol

In a study of 2,918 Japanese adults, carrying the G version of rs964184 was linked to higher triglycerides, lower HDL (the protective cholesterol), and higher fasting glucose. The same variant has been tied to metabolic syndrome (the cluster of high triglycerides, low HDL, high blood sugar, high blood pressure, and abdominal weight) in a 5,421-person study in Tehran, where ZPR1 variants jointly affected risk together with neighboring genes BUD13 and APOA5.

What this means for you: the at-risk version of ZPR1 pushes the entire triglyceride-HDL axis in the wrong direction, even when LDL looks acceptable. That matters because triglyceride-rich particles are an independent driver of atherosclerosis, and they are easy to underweight when only LDL is being tracked.

Type 2 Diabetes

The rs964184 G allele has been linked to a roughly 25 percent higher chance of having type 2 diabetes in a Japanese cohort (odds ratio 1.25). In a Han Chinese two-stage study of more than 10,000 people, a second variant, rs2075290, also showed a significant link to type 2 diabetes, and carriers of the higher-risk genotypes at both variants had higher fasting glucose and higher hemoglobin A1c.

The biological logic lines up with the broader role of this chromosomal region in fat and sugar handling. A genotype that sits inside that control system can shift your long-term glycemic trajectory by small amounts every year, which compounds over decades.

Fatty Liver

In a study of 185 adults with high triglycerides, rs964184 was independently linked to moderate or severe non-alcoholic fatty liver disease (now often called metabolic-associated steatotic liver disease, or fatty liver from metabolic causes). The link held after adjusting for body weight, insulin resistance, and other risk factors, meaning the genotype carried information that those standard measurements did not. A separate large genome-wide study in Taiwan independently identified ZPR1 as a shared risk gene for fatty liver, adding population-level support.

Diet Response

One practical finding comes from a sub-analysis of the CORDIOPREV study, a 523-person nested analysis within a larger trial in adults with established coronary heart disease. Over three years, carriers of the rs964184 G allele who followed a low-fat diet brought their post-meal triglycerides down to the same level as non-carriers. Carriers who followed a Mediterranean diet did not. The G allele appears to shift how your body handles dietary fat in a way that responds better to lower-fat eating patterns, at least in people with existing heart disease.

This finding should be read carefully. It is a secondary analysis of a subset of the parent CORDIOPREV trial, and the main trial found that overall, the Mediterranean diet was superior to the low-fat diet for hard cardiovascular outcomes in patients with established coronary disease. The genotype-by-diet result tells you something about post-meal triglyceride normalization, not about whether the diet switch prevents heart attacks.

One-Time Result

This is a once-in-a-lifetime test. Your ZPR1 genotype was set at conception and will not change. There is no value in retesting the genotype itself unless the result is ambiguous or a confirmatory method is needed to rule out a lab error.

The value of this result comes from how you use it over the next several decades. If you carry an at-risk variant, the action is not to repeat the test. It is to track the downstream phenotypes more aggressively: lipids (including triglycerides and ApoB, which counts atherogenic particles), fasting glucose and hemoglobin A1c (a three-month average of blood sugar), and markers of liver fat. A reasonable cadence is a full lipid and metabolic panel every 6 to 12 months, with tighter intervals if you are actively changing diet, weight, or medication.

Decision Pathway

If you carry an at-risk ZPR1 variant, the workup expands rather than contracts. Add ApoB and Lp(a) (lipoprotein little a, an inherited cardiovascular risk factor) to your standard lipid panel, because together they describe the particle-driven side of heart risk that triglycerides and LDL alone miss. Add hemoglobin A1c and fasting insulin to catch early insulin resistance before fasting glucose moves. Consider liver enzymes (ALT and GGT, both blood markers of liver stress) and, if any are elevated, imaging or a FibroScan to look at liver fat.

The pattern that warrants action is a combination, not a single threshold: rising triglycerides, falling HDL, ApoB drifting up, A1c creeping toward prediabetic territory, or liver enzymes nudging upward. A preventive cardiologist or lipidologist is a useful partner if more than one of these is moving in the wrong direction, especially before age 50. If you also have a family history of premature heart disease, a familial hypercholesterolemia evaluation is reasonable, since the strongest ZPR1 heart attack signal was seen in that population.

When Results Can Be Misleading

• Variant panel coverage: this test only reads the specific ZPR1 variants it is designed to detect, most often rs964184. A result that looks reassuring at that one variant does not rule out other less-studied changes in the same gene or region.
• Ethnic-specific frequencies: the at-risk versions of these variants occur at different rates in different ancestries, and most of the strongest outcome data come from Japanese, Chinese, Spanish, Indian, and Iranian cohorts. The size of the risk effect may not transfer one-to-one to other groups.
• Penetrance is partial: carrying a risk allele raises odds, it does not guarantee disease. Many carriers never develop the linked conditions, and many non-carriers do. The genotype is one input into a multi-factor picture, not a verdict.
• Secondary prevention populations: in people who already have established vascular disease, rs964184 has not been shown to predict recurrent events, even though it still tracks with triglyceride levels. The variant's predictive value sits more on the side of preventing a first event.
• Clinical-grade vs direct-to-consumer assays: if you have seen rs964184 in a 23andMe-style export, that read is generally accurate but not always clinically confirmed. A clinical-grade assay is the appropriate basis for medical decisions.

Reconciling the Evidence

You will see this gene linked to triglycerides in one paper, to diabetes in another, to fatty liver in a third, and to heart attacks in a fourth. That is not contradiction. ZPR1 sits inside a chromosomal region that influences how your liver, blood vessels, and metabolic tissues handle fat and sugar together. A genotype that nudges that system shows up wherever the downstream consequences are measured. Think of it less as a single-disease gene and more as a metabolic-tone setting that can manifest in different organs depending on the rest of your physiology.